6.34

9.04% -0.63

Capricor Therapeutics Inc (CAPR)

Overview News Price History Option Chain Financials Why CAPR Down? Discussions Forecast Stock Split

Capricor Therapeutics Inc stock is traded at $6.34, with a volume of 3.63M. It is down -9.04% in the last 24 hours and down -32.55% over the past month. Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

Previous Close:

$6.97

Open:

$6.99

24h Volume:

3.63M

Relative Volume:

2.24

Market Cap:

$541.73M

Revenue:

$27.10M

Net Income/Loss:

$-24.31M

P/E Ratio:

-7.6386

EPS:

-0.83

Net Cash Flow:

$-33.33M

1W Performance:

-46.54%

1M Performance:

-32.55%

6M Performance:

-67.82%

1Y Performance:

+16.97%

1-Day Range:

$6.27

$7.10

1-Week Range:

$6.27

$11.32

52-Week Range:

$3.52

$23.40

Capricor Therapeutics Inc Stock (CAPR) Company Profile

Name

Capricor Therapeutics Inc

Sector

Healthcare (1153)

Industry

Biotechnology (676)

Phone

(310) 358-3200

Address

8840 WILSHIRE BLVD, BEVERLY HILLS, CA

Employee

160

Twitter

@Capricor

Next Earnings Date

2025-03-19

Latest SEC Filings

CAPR's Discussions on Twitter

Compare CAPR with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CAPR Capricor Therapeutics Inc	6.34	541.73M	27.10M	-24.31M	-33.33M	-0.83
VRTX Vertex Pharmaceuticals Inc	424.99	128.84B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	527.78	65.38B	14.09B	4.50B	2.96B	39.28
ARGX Argen X Se Adr	549.65	39.67B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	251.15	33.82B	2.35B	-269.70M	-75.39M	-2.09
ONC Beigene Ltd Adr	231.99	27.60B	3.81B	-644.79M	-669.77M	-6.24

Capricor Therapeutics Inc Stock (CAPR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-21-24	Initiated	Piper Sandler	Overweight
May-17-24	Initiated	Oppenheimer	Outperform
Jan-05-24	Initiated	Cantor Fitzgerald	Overweight
Oct-26-22	Initiated	Ladenburg Thalmann	Buy
Dec-26-18	Downgrade	Maxim Group	Buy → Hold
Jan-26-18	Reiterated	H.C. Wainwright	Buy
Sep-15-17	Reiterated	H.C. Wainwright	Buy
Feb-13-17	Resumed	Rodman & Renshaw	Buy
Jul-06-16	Resumed	H.C. Wainwright	Buy
Jun-15-16	Initiated	ROTH Capital	Buy

View All

Capricor Therapeutics Inc Stock (CAPR) Latest News

May 09, 2025

Shareholders that lost money on Capricor Therapeutics, Inc. (CAPR) should contact Levi & Korsinsky about Securities Fraud InvestigationCAPR - ACCESS Newswire

May 09, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor ... - Bluefield Daily Telegraph

May 09, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - GlobeNewswire Inc.

May 09, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cable One, Inc. - GlobeNewswire Inc.

May 09, 2025

Capricor Therapeutics, Inc. (NASDAQ:CAPR) May Have Run Too Fast Too Soon With Recent 26% Price Plummet - simplywall.st

May 09, 2025

May 08, 2025

Levi & Korsinsky Investigates Possible Securities Fraud Violations by Capricor Therapeutics, Inc. (CAPR) - ACCESS Newswire

May 08, 2025

May 07, 2025

Capricor Therapeutics (NASDAQ:CAPR) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance

May 07, 2025

How the (CAPR) price action is used to our Advantage - news.stocktradersdaily.com

May 07, 2025

Vinay Prasad's Appointment To FDA's CBER Triggers Questions Over Future Of Cell And Gene Therapy Regulation - Benzinga

May 07, 2025

May 06, 2025

Capricor falls 12% as FDA orders panel to discuss Duchenne cardiomyopathy asset - MSN

May 06, 2025

Capricor Therapeutics to Present First Quarter 2025 Financial Re - GuruFocus

May 06, 2025

Capricor Therapeutics to Announce First Quarter 2025 Financial Results and Host Conference Call on May 13 - Nasdaq

May 06, 2025

Capricor Therapeutics to Present First Quarter 2025 Financial Results and Recent Corporate Update on May 13 - GlobeNewswire

May 06, 2025

May 05, 2025

Capricor Therapeutics (CAPR) Faces FDA Advisory Meeting for Duchenne Treatment | CAPR Stock News - GuruFocus

May 05, 2025

FDA adcomm will review Capricor's cell therapy for Duchenne muscular dystrophy - Endpoints News

May 05, 2025

US FDA to convene expert panel for Capricor Therapeutics' DMD cell therapy - Reuters

May 05, 2025

Capricor Therapeutics (CAPR) Faces FDA Advisory Meeting, Shares Drop - GuruFocus

May 05, 2025

Capricor Therapeutics Shares Fall as FDA Plans Panel Review for Duchenne Treatment - marketscreener.com

May 05, 2025

Capricor Share Slide 12% as FDA Calls Advisory Panel for Duchenne Cardiomyopathy Therapy - paginasiete.bo

May 05, 2025

Capricor Therapeutics Stock Tumbles After FDA Confirms Intent To Hold Advisory Committee Meet For Deramiocel Approval: But Retail’s Optimistic - Asianet Newsable

May 05, 2025

Capricor falls after FDA to hold advisory meeting for cell therapy - TradingView

May 05, 2025

Capricor Therapeutics (CAPR) Anticipates Positive FDA Review Despite Stock Dip | CAPR Stock News - GuruFocus

May 05, 2025

CAPR: Capricor Therapeutics Advances FDA Review for Deramiocel | CAPR Stock News - GuruFocus

May 05, 2025

Capricor Therapeutics Announces Completion of Mid-Cycle - GlobeNewswire

May 05, 2025

FDA Fast-Tracks Revolutionary DMD Heart Treatment as Capricor Clears Major Regulatory Hurdle - Stock Titan

May 05, 2025

Barclays PLC Has $1.24 Million Stock Holdings in Capricor Therapeutics Inc (NASDAQ:CAPR) - Defense World

May 05, 2025

May 04, 2025

Capricor Therapeutics Inc (NASDAQ:CAPR) Stock Position Lessened by JPMorgan Chase & Co. - Defense World

May 04, 2025

Capricor Therapeutics Inc (NASDAQ:CAPR) Receives $34.50 Consensus Target Price from Analysts - Defense World

May 04, 2025

May 03, 2025

Wells Fargo & Company MN Sells 4,641 Shares of Capricor Therapeutics Inc (NASDAQ:CAPR) - Defense World

May 03, 2025

May 02, 2025

Capricor Therapeutics Inc (NASDAQ: CAPR) Stock Gained 34.46% Over A Month – Any Room To Run? - Marketing Sentinel

May 02, 2025

May 01, 2025